Linagliptin

Product Name

Linagliptin

CAS No.

668270-12-0

Molecular Weight

472.54

Target

DPP-4

Synonyms

BI 1356

Formula

C25H28N8O2

Appearance

Solid

Purity

99.97%

IC50/EC50

IC50: 1 nM

SMILES

O=C1N(C2=C(C(N1CC3=NC(C)=C4C=CC=CC4=N3)=O)N(CC#CC)C(N5CCC[C@@H](N)C5)=N2)C

Description

Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM.

In Vitro Activity

Linagliptin inhibits DPP-4 activity in vitro in several independent experiments with IC50 values of 0.4, 0.5, 0.9, and 1.1 nM (mean IC50, approximately 1 nM). Linagliptin inhibits FAP with an IC50 of 89 nM (approximately 90-fold selectivity versus DPP-4).

In Vivo Activity

In male Wistar rats, Beagle dogs, and Rhesus monkeys, xanthine linagliptin proves to be a highly efficacious, long-lasting, and potent DPP-4 inhibitor providing >70% inhibition for >7 h for all three species after oral administration of 1 mg/kg. Single oral administration of linagliptin to db/db mice 45 min prior to an oral glucose tolerance test reduced plasma glucose excursion in a dose-dependent manner from 0.1 mg/kg (15% inhibition) to 1 mg/kg (66% inhibition). Linagliptin (3 and 10 mg/kg) dose-dependently inhibits the DPP-4 enzyme in plasma within 30 min of administration. Linagliptin (1 mg/kg) significantly reduces glucose excursion by approximately 50%. Oral administration of the DPP-4 inhibitor linagliptin (3 mg/kg) strongly reduces DPP-4 activity, stabilizes active GLP-1 in chronic wounds, and improves healing in ob/ob mice. At day 10 postwounding, linagliptin-treated ob/ob mice show largely epithelialized wounds characterized by the absence of neutrophils.

Storage

Powder, -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months, -20 °C, 1 month.

Shipping

Room temperature in continental US; may vary elsewhere.